Evaluation of the Periodontal Status After the Treatment of Palatally Impacted Canines Using Acceleration Procedures

December 11, 2022 updated by: Damascus University

Comparison of Posttreatment Periodontal Status of Palatally Impacted Canines Aligned by Conventional Versus Accelerated Minimally-invasive Corticotomy-assisted Orthodontic Traction Treatment: A Randomized Controlled Trial

Impacted canine causes many problems for patients, such as damage to the adjacent teeth roots, effects on gingival tissues, aesthetic problems, difficulty, and prolonged orthodontic treatment duration. Therefore, solutions to accelerate the movement of impacted canines with the help of surgical procedures to reduce treatment time will be investigated, such as intra-operative alveolar perforations and piezocision. We also aimed to evaluate periodontal changes associated with such accelerating procedures compared with the conventional traction method.

Study Overview

Status

Completed

Conditions

Detailed Description

Patients with palatally impacted maxillary canines will be treated using fixed appliances assisted by some surgical procedures. The effects of this treatment approach on the periodontal status will be assessed using periodontal measurements.

There are two groups :

  1. conventional treatment group
  2. minimally-invasive corticotomy-assisted treatment group Patients will be allocated to the two groups randomly. Data will be collected using periodontal variables.

Study Type

Interventional

Enrollment (Actual)

46

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 28 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Age of patients: 18-28 years.
  2. Palatal or Mid-alveolar impacted canine.
  3. There is no previous orthodontic treatment.
  4. Healthy periodontal tissues and good oral health (i.e., the Plaque Index is less or equal to 1 according to Loe and Silness(1963).
  5. The patient does not take any drug that may interfere with the tooth movement (Cortisone, NSAIDs …).
  6. Mild or no crowding on the upper jaw.
  7. No history of previous trauma to the maxillofacial region or surgical interventions.

Exclusion Criteria:

  1. Any systemic diseases that would affect tooth movement
  2. Antidepressant prevents oral surgery
  3. Any congenital syndromes or cleft lip and palate cases
  4. Bad oral health
  5. Previous orthodontic treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Conventional treatment
Patients will be treated using the fixed appliances to track the impacted canines after opening the appropriate distance
Metal brackets with a straight-wire prescription will be used. Patients will be treated conventionally.
Experimental: Surgically-assisted treatment
Patients will be treated using fixed appliances assisted by minimally-invasive corticotomy (alveolar perforations and piezocision) to accelerate impacted canines' traction after opening the appropriate distance.
Patients will be treated in conjunction with a surgical intervention using metal brackets with a straight-wire prescription. Corticotomy (alveolar perforation and piezocision) will induce acceleration in canine traction movement during the orthodontic treatment in only one group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in the periodontal pocket depth (PPD)
Time Frame: Time 1: immediately before the surgical exposure; Time 2: immediately at the end of the active treatment
The distance from the gingival margin to the base of the pocket of the first premolar, canine, and lateral incisor.
Time 1: immediately before the surgical exposure; Time 2: immediately at the end of the active treatment
Changes in the gingival margin (GM)
Time Frame: Time 1: immediately before the surgical exposure; Time 2: immediately at the end of the active treatment
The distance from the cementoenamel junction (CEJ) to the gingival margin of the first premolar, canine, and lateral incisor.
Time 1: immediately before the surgical exposure; Time 2: immediately at the end of the active treatment
Changes in the width of the keratinized tissue (KT)
Time Frame: Time 1: immediately before the surgical exposure; Time 2: immediately at the end of the active treatment
The distance from the gingival margin to the mucogingival junction of the first premolar, canine, and lateral incisor
Time 1: immediately before the surgical exposure; Time 2: immediately at the end of the active treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in the Bleeding Index (BI)
Time Frame: Time 1: immediately before the surgical exposure; Time 2: immediately at the end of the active treatment

The healthiness of the gingival margin and the attached gingivae will be assessed depending on the status of gingival inflammation.

0= No bleeding.

  1. Bleeding some seconds after probing.
  2. Bleeding immediately after probing.
  3. Bleeding on probing spreading towards the marginal gingiva.
Time 1: immediately before the surgical exposure; Time 2: immediately at the end of the active treatment
Changes in the Gingival Index (GI)
Time Frame: Time 1: immediately before the surgical exposure; Time 2: immediately at the end of the active treatment

The gingival status will be assessed using the following classification 0= Normal gingiva.

  1. Mild inflammation: slight color change, slight edema, No bleeding on probing.
  2. Moderate inflammation: redness, edema and glazing. Bleeding on probing.
  3. Severe inflammation: marked redness and edema. Tendency to spontaneous bleeding. Ulceration.
Time 1: immediately before the surgical exposure; Time 2: immediately at the end of the active treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Mahran R Mousa, DDS,MSc, Department of orthodontics, Damascus University, Syria
  • Study Director: Mohammad Y. Hajeer, DDS,MSc,PhD, Department of orthodontics, Damascus University, Syria
  • Study Director: Omar Heshmeh, DDS,MSc,PhD, Department of oral and maxillofacial surgery, Damascus University, Syriam

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 23, 2018

Primary Completion (Actual)

December 13, 2019

Study Completion (Actual)

November 15, 2022

Study Registration Dates

First Submitted

November 30, 2022

First Submitted That Met QC Criteria

November 30, 2022

First Posted (Actual)

December 9, 2022

Study Record Updates

Last Update Posted (Actual)

December 13, 2022

Last Update Submitted That Met QC Criteria

December 11, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UDDS-Ortho-15-2022

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe